LAVA Therapeutics NV Appoints KPMG as New Auditor, Dismisses PwC Amid Remediated Internal Control Weaknesses

Reuters
24 May
LAVA <a href="https://laohu8.com/S/LENZ">Therapeutics</a> NV Appoints KPMG as New Auditor, Dismisses PwC Amid Remediated Internal Control Weaknesses

LAVA Therapeutics NV has announced a change in its certifying accountants, appointing KPMG LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. This decision follows the dismissal of PricewaterhouseCoopers Accountants N.V. (PwC), which had previously audited the company's financial statements for 2023 and 2024. PwC's reports during these years contained no adverse opinions or disclaimers. However, the company had identified material weaknesses in its internal controls over financial reporting, specifically related to inadequate general controls over information technology and segregation of duties. These issues were successfully remediated by the end of 2024, as reported in their Annual Report filed in March 2025. PwC had discussed these matters with LAVA's Audit Committee, and the company has permitted PwC to fully inform KPMG about these past issues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LAVA Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-052460), on May 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10